Teva Pharmaceuticals signed a growth‑capital agreement with Blackstone Life Sciences that could deliver up to $400 million over four years to accelerate development of duvakitug, a monoclonal antibody targeting the TL1A inflammatory pathway. The financing includes regulatory and commercial milestone payments plus potential royalties, and follows Teva’s 2023 co‑development pact with Sanofi. Duvakitug is in Phase III studies for ulcerative colitis and Crohn’s disease (NCT07184931, NCT07184996). Blackstone said the investment aligns with its life‑sciences growth strategy; Teva framed the deal as part of a broader “Pivot to Growth” plan to bolster its pipeline while preserving financial discipline. The structure shifts late‑stage capital risk away from Teva’s balance sheet and links funding to development and commercial outcomes.